

XILCEF

PRESENTATION

XILCEF-500 CAPSULE

Each Capsule contains:

Cefadroxil USP equivalent to Anhydrous Cefadroxil 500 mg

Approved Colours used in capsule shell.

Supplied in a blister pack of 10 Capsules x 10 Blisters

XILCEF DRY SYRUP

Each 5mL of the reconstituted Suspension contains:

Cefadroxil USP equivalent to Anhydrous Cefadroxil 125 mg supplied in 30ml bottle

XILCEF 250 DRY SYRUP

Each 5mL of the reconstituted Suspension contains:

Cefadroxil USP equivalent to Anhydrous Cefadroxil 250 mg supplied in 30mL bottle

XILCEF 250 DT

Each dispersible tablet contains:

Cefadroxil USP equivalent to Anhydrous Cefadroxil 250 mg

Supplied in ALU-ALU blister pack of 10 Tablets x 10 Blisters

DESCRIPTION

Cefadroxil is a semisynthetic cephalosporin antibiotic intended for oral administration.

MECHANISM OF ACTION: It causes inhibition of cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs). Its action is bactericidal.

PHARMACOKINETIC:

Cefadroxil is rapidly absorbed after oral administration. Following single doses of 500 and 1000 mg, average peak serum concentrations were approximately 16 and 28 mcgm/mL, respectively. Over 90% of the drug is excreted unchanged in the urine within 24 hours. Peak urine concentrations are approximately 1800 mcgm/mL during the period following a single 500-mg oral dose. Increases in dosage generally produce a proportionate increase in Cefadroxil urinary concentration.

PATIENT COMPLIANCE:

Once daily dose of cefadroxil will have enhance patient compliance compared to cephalixin with dosed at 30mg/kg/day in twice or thrice daily schedule.

The overall results from this retrospective study suggest that cefadroxil is an effective agent with a favorable safety profile for the treatment of skin and skin-structure infections of the foot.

INDICATION

- Urinary tract infections, including bladder infections. caused by E. Coli, P. Mirabilis, and Klebsiella species
- Skin infections like Cellulitis, Furunculosis, Impetigo. by Staphylococci and/or Streptococci.
- Pharyngitis, Sore throat, including Strep. throat or infected tonsils. by Group A beta-hemolytic streptococci
- Bone infections, wound infections, Osteomyelitis, Septic arthritis.

NOTE: Culture and Susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.

DOSING SCHEDULE:

Adults

Skin/Skin Structure: Xilcef 500 capsule 1cap BID.

Pharyngitis/Tonsilitis: Xilcef 500 capsule 2caps OD or 1cap BID.

Cystitis: Xilcef 500 capsule 1cap BID.

Complicated UTI: Xilcef 500 capsule 2caps BID.

Children:

For children of weight 4.5kg, suspension containing 125mg/5ml dose is 2.5ml BID.

For children of weight 9.1kg, suspension containing 125mg/5ml dose is 5ml BID.

For children of weight upto 18.2kg, suspension containing 125mg/5ml dose is 10ml BID.

For further information, please contact:

Market Planning Department

Deurali-Janta Pharmaceuticals Pvt. Ltd.

GPO Box 4239, 355 Hattisar Road, Kamalpokhari, Kathmandu, Nepal.

Tel: 4435167/68/69 E-mail: mplanning@deuralijanta.com Website: www.deuralijanta.com

